MMAI

From Self-sufficiency
Revision as of 17:16, 12 May 2010 by Lukechadwick01010 (Talk) (Legality)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
MMAI
File:5-Methoxy-6-methyl-2-aminoindane.png
Systematic (IUPAC) name
5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 132980-16-6
ATC code none
PubChem CID 131575
ChemSpider 116274
Chemical data
Formula C11H15NO
Molar mass 177.242 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University.[1] It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans.[1][2][3] It has been sold as a designer drug online since 2010.[4]

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline,[5] and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs). Additionally it may relive symptoms for up to one year, or an entire lifetime of the user.[6]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. 1.0 1.1 Marona-Lewicka D, Nichols DE. (1994). "Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan". Eur J Pharmacol. 258 (1-2): 1–13. PMID 7925587. 
  2. Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD. (1996). "Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA)". J Pharmacol Exp Ther. 279 (3): 1261–1267. PMID 8968349. 
  3. Rudnick G, Wall SC. (1993). "Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters". Mol Pharmacol. 43 (2): 271–276. PMID 8429828. 
  4. "Latest Research Chemicals". 
  5. Marona-Lewicka D, Nichols DE. (1997). "The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats". Stress. 2 (2): 91–100. PMID 9787258. 
  6. Neuropharmacology. (1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Unfortunately as a research chemical it's legality is subject to change". Neuropharmacology. 38 (7): 1055–1061. PMID 10428424.